Abstract
HR 810, 3-〈(2,3-cyclopenteno-l -pyridinium)methyl〉-7-〈2-syn-methoximino-2-(2-aminothiazole-4-yl)-acetamido〉 ceph-3-em-4-carboxylate, is a new semisynthetic cephalosporin derivative. The in vitro activity of HR810 was compared with that of cefotaxime, ceftazidime, piperacillin and gentamicin using 368 strains of gram-negative and gram-positive bacteria. HR 810 was highly active againstEnterobacteriaceae, being the most active of the cephalosporins againstEnterobacter, Serratia andCitrobacter spp.; the MICs ranged from ≤0.06 to 8mg/l. The activity of HR 810 againstPseudomonas aeruginosa andAcinetobacter spp. was almost as good as that of ceftazidime. The new compound was superior to the other cephalosporins againstStaphylococcus aureus and inhibited allStreptococcus faecalis strains at a concentration of 16 mg/l.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Committee for Clinical Laboratory Standards: Proposed standard PSM-7. Standard method for dilution antimicrobial susceptibility tests for bacteria which grow aerobically. NCCLS, Villanova, PA, 1980.
Kayser, F., Machka, K., Wieczorek, L., Banauch, D., Bablok, W., Braveny, I.: Evaluation of the Micur microdilution systems for antibiotic susceptibility testing of gram-negative and gram positive bacteria. European Journal of Clinical Microbiology 1982, 1: 361–366.
Prehejm, L. C., Penn, R. G., Sanders, C. C., Goering, R. V., Giger, D. K.: Emergence of resistance toβ-lactam and aminoglycoside antibiotics during moxalactam therapy ofPseudomonas aeruginosa infections. Antimicrobial Agents and Chemotherapy 1982, 22: 1037–1041.
Platt, R., Ehrlich, S. L., Afarian, J., O'Brien, T. F., Pennington, J. E., Kass, E. H.: Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrobial Agents and Chemotherapy 1981, 20: 351–355.
Bauernfeind, A.: Susceptibility of gram-positive aerobic cocci to to the new cephalosporin HR 810. European Journal of Clinical Microbiology 1983, 2: 354–355.
Seeberg, A. H., Tolxdorff-Neutzling, R. M., Wiedemann, B.: Chromosomalβ-lactamases ofEnterobacter cloacae are responsible for resistance to third-generation cephalosporins. Antimicrobial Agents and Chemotherapy 1983, 23: 918–925.
Cullmann, W., Opferkuch, W., Stieglitz, M.: Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime. European Journal of Clinical Microbiology 1983, 2: 350–352.
Tolxdorff-Neutzling, R. M., Wiedemann, B.: HR 810, a cephalosporin with low affinity forEnterobacter cloacae beta-lactamase. European Journal of Clinical Microbiology 1983, 2: 352–354.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Machka, K., Braveny, I. In vitro activity of HR 810, a new broad-spectrum cephalosporin. Eur. J, Clin. Microbiol. 2, 345–349 (1983). https://doi.org/10.1007/BF02019465
Issue Date:
DOI: https://doi.org/10.1007/BF02019465